Physician profile
Alla Chikhman
NPI 1114063120
$9,049.31
in general payments reported to CMS, 2019-2025
36 companies · $814 in 2025
The $814 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $1,619 · 2021: $1,753 · 2022: $1,550 · 2023: $1,455 · 2024: $1,394 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,662 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.97 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,497.17 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Dexcom, INC. | $1,048.36 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $906.31 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $834.86 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $794.38 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $618.90 | 2019-2022 | |
| Lilly USA, LLC | $532.13 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $504.94 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $194.12 | 2019-2022 | |
| Amgen INC. | $183.66 | 2020-2025 | Krystexxa, Prolia, Evenity |
| Astellas Pharma US INC | $181.91 | 2019-2022 | |
| Allergan, INC. | $181.88 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $172.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $161.72 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $138.35 | 2020-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Chikhman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.